Repurposing Thalidomide Derivatives To Augment Cancer Immunotherapy
Funder
National Health and Medical Research Council
Funding Amount
$1,154,196.00
Summary
Immunotherapies are a revolutionary approach for cancer treatment, but most people with cancer do not respond to therapy. We have identified a new set of molecular switches that shutdown immune function and limit responsiveness to existing immunotherapies. Importantly, we have found a class of approved drugs that can block these immune 'off switches'. This proposal will test if these drugs could be repurposed as a novel treatment to amplify the efficacy of existing immunotherapies.
Characterisation And Targeting T Cellular Metabolism To Improve Control Of Chronic Viral Infections
Funder
National Health and Medical Research Council
Funding Amount
$791,427.00
Summary
CD8+ T cells are the frontline warriors of our immune system that can eliminate infected or cancerous cells. However, diseases caused by overwhelming viral infections are associated with widespread impairments in immunity and cellular metabolism. Here, we propose to examine molecular pathways involved in cellular metabolism that could be utilized to improve therapies against viral infection and cancer.
A Roadmap For Aboriginal And Torres Strait Islander Adolescent Health: Defining Priority Health Needs And Actions Through The Empowerment & Capacity Development Of Young People.
Funder
National Health and Medical Research Council
Funding Amount
$2,002,448.00
Summary
A third of the Indigenous population are adolescents, their health central to cultural continuity and health equity. Yet priority health needs and evidence-based responses for Indigenous adolescents remain poorly defined, a barrier to effective policy. The project is significant because it will establish a roadmap to guide actions around Indigenous adolescent health. It will also result in a network of engaged and up-skilled Indigenous young people who can drive implementation.
Investigating The Role Of Mitochondrial Tom40 In Regulated Cell Death And Neurodegeneration.
Funder
National Health and Medical Research Council
Funding Amount
$972,660.00
Summary
Mitochondria are internal compartments of cells, separated by bounding membranes. They are crucial to the life and death of cells, and to quality of human life and ageing. Diseases of the nervous system can be caused when mitochondria do not function properly. Our aim is to discover why a protein complex called TOM embedded in the bounding membrane is linked to dementia in some people. This will also lead to a better general understanding of the connection between mitochondria and human health.
Targeting A Bacterial Glyco-Achilles Heel To Make New Vaccines For Haemophilus Influenzae And Neisseria Gonorrhoeae.
Funder
National Health and Medical Research Council
Funding Amount
$526,950.00
Summary
The bacteria that cause gonorrhoea (N. gonorrhoeae), middle ear infections and exacerbations of chronic obstructive lung disease (H. influenzae) have become multi-drug resistant. These diseases are a major health and economic burden. In the absence of new drugs, a vaccine to prevent these diseases has emerged as a major unmet need in human health. In this grant, we will develop a new vaccine that targets a bacterial-specific sugar that we have discovered is the Achilles heel of these bacteria.
This study aims to elucidate central pathways which can be manipulated to drive the storage of excess energy away from fat and instead directing it into the production of bone mass. Having identified leptin-responsive NPY neurons as important in the control of energy partitioning, we will focus on manipulating these neurons in the hypothalamus using innovative technology to alter body composition. This research has the potential to result in novel treatments for obesity and osteoporosis.
Molecular Regulators Of Adaptive Immunity To Overwhelming Viral Infections
Funder
National Health and Medical Research Council
Funding Amount
$786,898.00
Summary
Diseases caused by overwhelming viral infections, such as COVID-19, are associated with widespread impairments in immunity and constitute a major burden to human health. We have discovered that the molecule c-Myb is essential for the maintenance of immunity during chronic infection. In order to lay the foundations for novel and innovative anti-viral therapies, this project will dissect the molecular pathways regulated by c-Myb that maintain immunity during severe or chronic infection.
Uncovering Oxytocin And Vasopressin Release And Functions With Novel Optical Tools
Funder
National Health and Medical Research Council
Funding Amount
$631,634.00
Summary
Oytocin and vasopressin are peptides in the brain that act as releasable neuromodulators and the balance of these peptides is implicated in the control of social behaviour and anxiety. We aim to investigate the release and function of these neuropeptides with 3 novel protein-based tools in a stressful learning paradigm and anxious behaviour. The understanding of their function will have important implications in the development of therapeutics for neurological conditions and drug addictions.
Development Of Novel Anti-malaria Drugs That Block Parasite Invasion
Funder
National Health and Medical Research Council
Funding Amount
$1,035,623.00
Summary
Malaria is a devastating parasitic disease that kills over 400,000 people a year. Antimalarial drugs play a crucial role in helping eradicate malaria but of great concern is that parasites are becoming resistant to current drugs. We are developing drugs that prevent parasites from invading and proliferating in human blood which causes malaria. We are also discovering how the drugs work with the aim of greatly improving their performance towards clinical uptake.
Exploiting Messenger RNA Export As A Novel Therapeutic Strategy To Treat Cancer
Funder
National Health and Medical Research Council
Funding Amount
$948,098.00
Summary
Novel therapies for cancers represent an area of unmet clinical need. We have identified a new biological pathway implicated in cancer, namely selective mRNA export. Compounds inhibiting other steps of the gene expression pathway are promising therapeutic candidates for cancer, yet mRNA export inhibitors do not exist. We propose to develop first-in-class inhibitors of mRNA export that selectively target transcriptionally addicted cancers with dysregulated RNA processing.